SCHEMBL5362076

SCHEMBL5362076

Cc1cc(C=C2C(=O)Nc3c(Br)cc(Br)cc32)cc(C)c1O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 4/20 0.52
SIRT1 Q96EB6 3/20 0.48
MAP1LC3B Q9GZQ8 3/20 0.48
SIRT2 Q8IXJ6 2/20 0.48
SIRT3 Q9NTG7 2/20 0.48
EEF2K O00418 1/20 0.47
SRC P12931 1/20 0.47
RAF1 P04049 6/20 0.46
PLK4 O00444 3/20 0.43
PLK1 P53350 2/20 0.43
MEN1 O00255 2/20 0.43
LMNA P02545 2/20 0.43
POLB P06746 2/20 0.43
MAPT P10636 2/20 0.43
KMT2A Q03164 2/20 0.43
NTRK1 P04629 2/20 0.43
PSEN1 P49768 1/20 0.43
PSEN2 P49810 1/20 0.43
APH1B Q8WW43 1/20 0.43
NCSTN Q92542 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5370420 0.90 ERBB2 (0.51) LRRK2SIRT1MAP1LC3BSIRT2SIRT3
SCHEMBL7134818 0.86 MAP1LC3B (0.60) LRRK2SIRT1MAP1LC3BSIRT2SIRT3
SCHEMBL7131372 0.85 SIRT1 (0.48) LRRK2SIRT1MAP1LC3BSIRT2SIRT3
SCHEMBL5365913 0.85 LRRK2 (0.54) LRRK2SIRT1MAP1LC3BSIRT2SIRT3
SCHEMBL5362718 0.84 MAP1LC3B (0.67) LRRK2SIRT1MAP1LC3BSIRT2SIRT3
SCHEMBL5363945 0.84 ERBB2 (0.58) SIRT1MAP1LC3BSIRT2SIRT3EEF2K
SCHEMBL5366147 0.84 EGFR (0.58) LRRK2SIRT1MAP1LC3BSIRT2SIRT3
SCHEMBL6697120 0.83 RAF1 (0.54) LRRK2SIRT1MAP1LC3BSIRT2SIRT3
SCHEMBL5361431 0.82 METAP1 (0.54) LRRK2SIRT1MAP1LC3BSIRT2SIRT3
SCHEMBL5366145 0.82 EGFR (0.53) LRRK2SIRT1MAP1LC3BSIRT2SIRT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK LRRK2 289/4885SIRT1 3834/4885MAP1LC3B 1427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.